Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 28;10:7142. doi: 10.1038/s41598-020-64155-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Pep19-2.5 inhibits FXI but not plasma kallikrein. Pooled diluted plasma was incubated with Pep19-2.5, and Dapptin was added for FXII activation. In the pos. control Dapptin (without peptid) and in the neg. control water was added. (A) PK/FXIIa activity was determined with the substrate S-2302 over a period of 120 min. One representative experiment from 2 is shown. (B) PK/FXIIa activity in plasma after 30 min incubation with Dapptin and different concentration of Pep19-2.5 is shown. The pos. control (Dapptin without peptide) was set to 100%. Data from 2 independent experiments were pooled. (C) FXI activity was determined with the substrate S-2366 over a period of 120 min. One representative experiment from 3 is shown. (D) FXI activity in plasma after 30 min incubation with Dapptin and different concentration of Pep19-2.5 is shown. The pos. control (Dapptin without peptide) was set to 100%. Data from 3 independent experiments were pooled. **p = 0.0014, ***p = 0.0003, ****p < 0.0001.